US 20200147171A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2020/0147171 A1**

Aldhamen et al. (43) **Pub. Date: May 14, 2020**

(54) **COMPOSITIONS OF CRACC FUSIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE AGAINST CANCERS, INFECTIONS DISEASES AND DISORDERS**

(71) Applicant: **Board of Trustees of Michigan State University**, East Lansing, MI (US)

(72) Inventors: **Yasser A. Aldhamen**, East Lansing, MI (US); **Andrea Amalfitano**, East Lansing, MI (US)

(21) Appl. No.: **16/574,397**

(22) Filed: **Sep. 18, 2019**

Related U.S. Application Data

(60) Provisional application No. 62/732,975, filed on Sep. 18, 2018.

Publication Classification

(51) **Int. Cl.**

A61K 38/17	(2006.01)
C12N 15/86	(2006.01)
A61P 35/00	(2006.01)
A61K 45/06	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 38/177*** (2013.01); ***C12N 15/86*** (2013.01); *C12N 2710/10343* (2013.01); ***A61K 45/06*** (2013.01); ***A61P 35/00*** (2018.01)

(57) **ABSTRACT**

The present invention relates to compositions and methods for modulating immune responses using at least one CRACC composition comprising an adenoviral vector comprising at least one CRACC fusion. Such CRACC compositions may be combined with a number of other therapeutic agents which target modulating immune responses, as well as, treatments that include immune events.

Specification includes a Sequence Listing.